These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1172 related articles for article (PubMed ID: 37306737)

  • 1. Expression of tumor-associated macrophages and PD-L1 in patients with hepatocellular carcinoma and construction of a prognostic model.
    Kong P; Yang H; Tong Q; Dong X; Yi MA; Yan D
    J Cancer Res Clin Oncol; 2023 Sep; 149(12):10685-10700. PubMed ID: 37306737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preferential Expression of Programmed Death Ligand 1 Protein in Tumor-Associated Macrophages and Its Potential Role in Immunotherapy for Hepatocellular Carcinoma.
    Park DJ; Sung PS; Lee GW; Cho S; Kim SM; Kang BY; Hur W; Yang H; Lee SK; Lee SH; Jung ES; Seo CH; Ahn J; Choi HJ; You YK; Jang JW; Bae SH; Choi JY; Yoon SK
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD86⁺/CD206⁺, Diametrically Polarized Tumor-Associated Macrophages, Predict Hepatocellular Carcinoma Patient Prognosis.
    Dong P; Ma L; Liu L; Zhao G; Zhang S; Dong L; Xue R; Chen S
    Int J Mol Sci; 2016 Mar; 17(3):320. PubMed ID: 26938527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MARCKS on Tumor-Associated Macrophages is Correlated with Immune Infiltrates and Poor Prognosis in Hepatocellular Carcinoma.
    Ren X; Ju Y; Wang C; Wei R; Sun H; Zhang Q
    Cancer Invest; 2021 Oct; 39(9):756-768. PubMed ID: 34279157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance and immune characteristics of CMTM4 in hepatocellular carcinoma.
    Tan S; Guo X; Bei C; Zhang H; Li D; Zhu X; Tan H
    BMC Cancer; 2022 Aug; 22(1):905. PubMed ID: 35986302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma.
    Chen DP; Ning WR; Jiang ZZ; Peng ZP; Zhu LY; Zhuang SM; Kuang DM; Zheng L; Wu Y
    J Hepatol; 2019 Aug; 71(2):333-343. PubMed ID: 31071366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. M1 Macrophages Induce PD-L1 Expression in Hepatocellular Carcinoma Cells Through IL-1β Signaling.
    Zong Z; Zou J; Mao R; Ma C; Li N; Wang J; Wang X; Zhou H; Zhang L; Shi Y
    Front Immunol; 2019; 10():1643. PubMed ID: 31379842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 10. Prognostic impact of programmed cell death 1 ligand 1 expression in human leukocyte antigen class I-positive hepatocellular carcinoma after curative hepatectomy.
    Umemoto Y; Okano S; Matsumoto Y; Nakagawara H; Matono R; Yoshiya S; Yamashita Y; Yoshizumi T; Ikegami T; Soejima Y; Harada M; Aishima S; Oda Y; Shirabe K; Maehara Y
    J Gastroenterol; 2015 Jan; 50(1):65-75. PubMed ID: 24509608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma.
    Zhang W; Liu Y; Yan Z; Yang H; Sun W; Yao Y; Chen Y; Jiang R
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. USP7 targeting modulates anti-tumor immune response by reprogramming Tumor-associated Macrophages in Lung Cancer.
    Dai X; Lu L; Deng S; Meng J; Wan C; Huang J; Sun Y; Hu Y; Wu B; Wu G; Lovell JF; Jin H; Yang K
    Theranostics; 2020; 10(20):9332-9347. PubMed ID: 32802195
    [No Abstract]   [Full Text] [Related]  

  • 13. M2-type tumor-associated macrophages upregulated PD-L1 expression in cervical cancer via the PI3K/AKT pathway.
    Guo F; Kong W; Li D; Zhao G; Anwar M; Xia F; Zhang Y; Ma C; Ma X
    Eur J Med Res; 2024 Jul; 29(1):357. PubMed ID: 38970071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intrahepatic inflammatory IgA
    Sung PS; Park DJ; Roh PR; Mun KD; Cho SW; Lee GW; Jung ES; Lee SH; Jang JW; Bae SH; Choi JY; Choi J; Ahn J; Yoon SK
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35577505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significant correlation between HSPA4 and prognosis and immune regulation in hepatocellular carcinoma.
    Shang BB; Chen J; Wang ZG; Liu H
    PeerJ; 2021; 9():e12315. PubMed ID: 34754620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipopolysaccharide facilitates immune escape of hepatocellular carcinoma cells via m6A modification of lncRNA MIR155HG to upregulate PD-L1 expression.
    Peng L; Pan B; Zhang X; Wang Z; Qiu J; Wang X; Tang N
    Cell Biol Toxicol; 2022 Dec; 38(6):1159-1173. PubMed ID: 35438468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression patterns of programmed death ligand 1 correlate with different microenvironments and patient prognosis in hepatocellular carcinoma.
    Liu CQ; Xu J; Zhou ZG; Jin LL; Yu XJ; Xiao G; Lin J; Zhuang SM; Zhang YJ; Zheng L
    Br J Cancer; 2018 Jul; 119(1):80-88. PubMed ID: 29921949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
    Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
    Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High expression of PDZ-binding kinase is correlated with poor prognosis and immune infiltrates in hepatocellular carcinoma.
    Mu W; Xie Y; Li J; Yan R; Zhang J; Liu Y; Fan Y
    World J Surg Oncol; 2022 Jan; 20(1):22. PubMed ID: 35065633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prognostic Analysis of NSCLC Based on the Tumor-associated Macrophages, Tumor Neo-vessels and PD-L1 Expression in Tumor Microenvironment].
    Hang Q; Ying H; Cheng G; Yang S; Jin J; Chen Y; Chen Q; Jiang Y; Zhao Q; Fang M; Chen M; Lai X
    Zhongguo Fei Ai Za Zhi; 2020 Oct; 23(10):837-844. PubMed ID: 33070512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 59.